Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...

--Up 15.51% from 52 weeks ago (Jan. 16, 2024), when it closed at $634.57 --Down 23.65% from its 52-week closing high of $960.02 on Aug. 30, 2024 --Up 17.59% from its 52-week closing low of $623.35 on ...

Eli Lilly and Company (LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B.

Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Ricks said at the JPMorgan Healthcare Conference that the government needs to "fix" the Inflation Reduction Act (IRA) before ...